Côte d'Ivoire

The primary regulatory authority for health products in Côte d'Ivoire is the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML), operating under the Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle. The legal framework is anchored in the Public Health Code (Loi n° 2015-533 du 20 juillet 2015) and supplementary ministerial decrees governing the registration, importation, distribution, and post-market surveillance of pharmaceuticals, medical devices, in-vitro diagnostics, and related health products. All health products intended for the Ivorian market must obtain a Marketing Authorization (Autorisation de Mise sur le Marché, AMM) prior to commercialization, following technical evaluation by the DPML and advisory review by the Comité Technique Consultatif des Médicaments (CTCM).

Applications for marketing authorization must be submitted in French and are generally expected to follow Common Technical Document (CTD) formatting, which aligns with the broader harmonization agenda of the West African Health Organisation (WAHO) and the ECOWAS regional framework. A local representative or registered pharmaceutical company established in Côte d'Ivoire is required to sponsor and maintain the dossier. Supporting documentation typically includes quality, safety, and efficacy data, certificates of pharmaceutical product (CPP) from the country of manufacture, Good Manufacturing Practice (GMP) certification, and labeling compliant with national requirements. Côte d'Ivoire has been progressively aligning with the African Medicines Regulatory Harmonization (AMRH) initiative and participates in the ECOWAS Pharmaceutical Policy, with ongoing reforms aimed at reducing duplicative review burdens, strengthening post-market surveillance capacity, and establishing clearer pathways for medical devices and digital health solutions.

Public procurement of health products in Côte d'Ivoire is centrally coordinated through the Centrale d'Achat des Médicaments Essentiels, Vaccins et Consommables Médicaux (CAMEG), which serves as the primary government entity responsible for the quantification, procurement, storage, and distribution of essential medicines, vaccines, and medical consumables to public health facilities nationwide. The Ministry of Health, de l'Hygiène Publique et de la Couverture Maladie Universelle provides strategic direction and budget oversight, while public tenders are governed by the national public procurement framework administered by the Autorité Nationale de Régulation des Marchés Publics (ANRMP). Procurement processes for large-volume or high-value health products typically require open competitive tendering, compliance with national registration requirements, and may involve technical evaluation committees. The country does not operate a federal-state procurement split; the system is largely centralized, though district-level health facilities may manage limited local purchases within defined budget envelopes.

The private health sector in Côte d'Ivoire is substantial, encompassing private pharmacies, clinics, and hospital networks that procure health products through licensed importers and distributors operating outside the public tender system, with pricing subject to national regulatory ceilings for essential medicines. Côte d'Ivoire is a significant recipient of donor-funded health programs, with major international partners including the Global Fund to Fight AIDS, Tuberculosis and Malaria, PEPFAR via USAID, Gavi the Vaccine Alliance, UNICEF, and the World Bank, all of which channel procurement through coordinated mechanisms that may bypass CAMEG or operate in parallel supply chains governed by donor-specific procurement rules. Products procured under donor programs must still meet national registration requirements or qualify for a defined exemption or emergency waiver. While Côte d'Ivoire does not yet have a robust local pharmaceutical manufacturing sector to support formal local content preferences, national health policy documents express aspirations to develop domestic production capacity in alignment with the African Union's Pharmaceutical Manufacturing Plan for Africa, and future procurement policies may increasingly incentivize regionally manufactured products.